NCT_ID,Sponsor,Study_Name,Start_Date,End_Date,Current_Status,Treatment,Facility,Lat,Lon
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,BC Children's Hospital,49.24966,-123.11934
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,BC Children's Hospital,49.24966,-123.11934
NCT06079736,PepGen Inc,"A Phase 2, Open-Label, Multiple Ascending Dose Study of PGN-EDO51 With a Long-Term Extension in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (CONNECT1-EDO51)",2023-09-29,2027-11,RECRUITING,ASO,BC Children's Hospital,49.24966,-123.11934
NCT06642662,Boston Children's Hospital,Exploring Precision Medicine in the CICU: Feasibility of Proteomic Biomarkers,2024-10-09,2026-12,NOT_YET_RECRUITING,ASO,Boston Children's Hospital,42.35843,-71.05977
NCT04740476,"Stoke Therapeutics, Inc",An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001,2021-02-02,2027-03-03,ENROLLING_BY_INVITATION,ASO,Massachusetts General Hospital,42.35843,-71.05977
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,Boston Children's Hospital,42.35843,-71.05977
NCT03225846,Wave Life Sciences Ltd.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease",2017-07-17,2021-05-10,TERMINATED,ASO,Massachusetts General Hospital,42.35843,-71.05977
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,Boston Children's Hospital,42.35843,-71.05977
NCT02532764,ProQR Therapeutics,"Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis",2015-08-13,2017-09-14,COMPLETED,ASO,Massachusetts General Hospital,42.35843,-71.05977
NCT02532764,ProQR Therapeutics,"Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis",2015-08-13,2017-09-14,COMPLETED,ASO,Boston Children's Hospital,42.35843,-71.05977
NCT02353351,Abbott Medical Devices,Closure of Atrial Septal Defects With the AMPLATZER™ Septal Occluder (ASO) Post Market Surveillance Study,2014-12-02,2017-02-24,TERMINATED,ASO,Boston Children's Hospital,42.35843,-71.05977
NCT02353351,Abbott Medical Devices,Closure of Atrial Septal Defects With the AMPLATZER™ Septal Occluder (ASO) Post Market Surveillance Study,2014-12-02,2017-02-24,TERMINATED,ASO,Children's Hospital Los Angeles,34.05223,-118.24368
NCT06609889,University of Texas Southwestern Medical Center,A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease,2024-08-10,2028-10,RECRUITING,ASO,Children's Health Dallas,32.78306,-96.80667
NCT04740476,"Stoke Therapeutics, Inc",An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001,2021-02-02,2027-03-03,ENROLLING_BY_INVITATION,ASO,Children's Health Colorado,39.72943,-104.83192
NCT03605069,Phoenicis Therapeutics,"A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene",2018-06-25,2018-12-17,TERMINATED,ASO,Children's Health Colorado,39.72943,-104.83192
NCT06565572,"University of Colorado, Denver","An Open-label Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for PCARP (Posterior Column Ataxia with Retinitis Pigmentosa) Disease Due to Mutations in FLVCR1",2023-08-09,2028-12-31,ENROLLING_BY_INVITATION,ASO,Children's Health Colorado,39.72943,-104.83192
NCT04442295,"Stoke Therapeutics, Inc",An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome,2020-06-08,2024-04-03,COMPLETED,ASO,Children's Health Colorado,39.72943,-104.83192
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,Children's Hospital of Eastern Ontario,45.41117,-75.69812
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,Children's Hospital of Eastern Ontario,45.41117,-75.69812
NCT06079736,PepGen Inc,"A Phase 2, Open-Label, Multiple Ascending Dose Study of PGN-EDO51 With a Long-Term Extension in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (CONNECT1-EDO51)",2023-09-29,2027-11,RECRUITING,ASO,Children's Hospital of Eastern Ontario,45.41117,-75.69812
NCT04740476,"Stoke Therapeutics, Inc",An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001,2021-02-02,2027-03-03,ENROLLING_BY_INVITATION,ASO,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT04442295,"Stoke Therapeutics, Inc",An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome,2020-06-08,2024-04-03,COMPLETED,ASO,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT02353351,Abbott Medical Devices,Closure of Atrial Septal Defects With the AMPLATZER™ Septal Occluder (ASO) Post Market Surveillance Study,2014-12-02,2017-02-24,TERMINATED,ASO,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,ASO,Children's Mercy Kansas City,39.09973,-94.57857
NCT03605069,Phoenicis Therapeutics,"A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene",2018-06-25,2018-12-17,TERMINATED,ASO,Cincinnati Children's Hospital,39.12713,-84.51435
NCT02564354,ProQR Therapeutics,"Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the ΔF508 CFTR Mutation",2015-09-29,2016-09,COMPLETED,ASO,Cincinnati Children's Hospital,39.12713,-84.51435
NCT03907072,Wave Life Sciences Ltd.,"A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)",2019-04-05,2020-01-09,TERMINATED,ASO,Kennedy Krieger Institute,39.29038,-76.61219
NCT04740476,"Stoke Therapeutics, Inc",An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001,2021-02-02,2027-03-03,ENROLLING_BY_INVITATION,ASO,Mayo Clinic,44.02163,-92.4699
NCT06397001,Mayo Clinic,"An Open-label Single Center, Single Patient Study of an Experimental Antisense Oligonucleotide (ASO) Treatment in AA Amyloidosis",2024-04-30,2025-01,ACTIVE_NOT_RECRUITING,ASO,Mayo Clinic,44.02163,-92.4699
NCT01563302,"Ionis Pharmaceuticals, Inc.","A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers",2012-02-13,2016-03-23,COMPLETED,ASO,Mayo Clinic,44.02163,-92.4699
NCT04442295,"Stoke Therapeutics, Inc",An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome,2020-06-08,2024-04-03,COMPLETED,ASO,Mayo Clinic,44.02163,-92.4699
NCT04740476,"Stoke Therapeutics, Inc",An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001,2021-02-02,2027-03-03,ENROLLING_BY_INVITATION,ASO,Nicklaus Children's Hospital,25.77427,-80.19366
NCT04442295,"Stoke Therapeutics, Inc",An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome,2020-06-08,2024-04-03,COMPLETED,ASO,Nicklaus Children's Hospital,25.77427,-80.19366
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,Weill Cornell Medicine,40.71427,-74.00597
NCT04485949,Imvax,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma",2020-07-22,2027-07,ACTIVE_NOT_RECRUITING,ASO,Weill Cornell Medicine,40.71427,-74.00597
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,Weill Cornell Medicine,40.71427,-74.00597
NCT04050852,NYU Langone Health,Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen Treatments,2019-08-07,2021-04-01,WITHDRAWN,ASO,NYU Langone Health,40.71427,-74.00597
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,ASO,Rady Children's Hospital,32.71533,-117.15726
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,ASO,Rady Children's Hospital,32.71533,-117.15726
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,Rady Children's Hospital,32.71533,-117.15726
NCT06314490,"University of California, San Diego",Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A,2024-03-01,2026-02-16,ACTIVE_NOT_RECRUITING,ASO,Rady Children's Hospital,32.71533,-117.15726
NCT02353351,Abbott Medical Devices,Closure of Atrial Septal Defects With the AMPLATZER™ Septal Occluder (ASO) Post Market Surveillance Study,2014-12-02,2017-02-24,TERMINATED,ASO,Rady Children's Hospital,32.71533,-117.15726
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,Rush University Medical Center,41.85003,-87.65005
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,ASO,Rush University Medical Center,41.85003,-87.65005
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,Rush University Medical Center,41.85003,-87.65005
NCT06079346,Mateon Therapeutics,A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer,2023-09-29,2027-06-01,RECRUITING,ASO,Baylor College of Medicine,29.76328,-95.36327
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,ASO,"Baylor College of Medicine, Texas Children's Hospital",29.76328,-95.36327
NCT04442295,"Stoke Therapeutics, Inc",An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome,2020-06-08,2024-04-03,COMPLETED,ASO,UCSF Benioff Children's Hospital,37.77493,-122.41942
NCT03225846,Wave Life Sciences Ltd.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease",2017-07-17,2021-05-10,TERMINATED,ASO,Vanderbilt University Medical Center,36.16589,-86.78444
NCT03761849,Hoffmann-La Roche,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease",2018-11-30,2022-03-24,COMPLETED,ASO,Vanderbilt University Medical Center,36.16589,-86.78444
NCT04539041,Novartis,"A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy",2020-08-25,2024-10-17,COMPLETED,ASO,Vanderbilt University Medical Center,36.16589,-86.78444
NCT05683860,Wave Life Sciences Ltd.,"A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)",2023-01-04,2023-06-30,TERMINATED,ASO,Erasmus MC,51.9225,4.47917
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,Universitaetsklinikum Leipzig,51.33962,12.37129
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,Universitaetsklinikum Leipzig,51.33962,12.37129
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,Corporacio Sanitaria Parc Tauli - Hospital de Sabadell,41.54329,2.10942
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,ASO,Corporacio Sanitaria Parc Tauli,41.54329,2.10942
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,Edmond and Lily Safra Children's Hospital,32.08227,34.81065
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,Queensland Children's Hospital,-27.48034,153.02049
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,Queensland Children's Hospital,-27.48034,153.02049
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,Royal Children's Hospital,-37.814,144.96332
NCT05032196,Wave Life Sciences Ltd.,"A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease (SELECT-HD)",2021-08-18,2024-05-24,COMPLETED,ASO,Royal Children's Hospital,-37.814,144.96332
NCT03605069,Phoenicis Therapeutics,"A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene",2018-06-25,2018-12-17,TERMINATED,ASO,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT02532764,ProQR Therapeutics,"Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis",2015-08-13,2017-09-14,COMPLETED,ASO,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT02564354,ProQR Therapeutics,"Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the ΔF508 CFTR Mutation",2015-09-29,2016-09,COMPLETED,ASO,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT04433520,Abbott Medical Devices,Amplatzer™Trevisio™Delivery System Post-Approval Study,2020-06-12,2025-10-15,ACTIVE_NOT_RECRUITING,ASO,HÃ´pital de la Timone,43.29551,5.38958
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,ASO,HÃ´pital de la Timone,43.29551,5.38958
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,ASO,HÃ´pital de la Timone,43.29551,5.38958
NCT03907072,Wave Life Sciences Ltd.,"A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)",2019-04-05,2020-01-09,TERMINATED,ASO,Les HÃ´pitaux Universitaires de Strasbourg,48.58392,7.74553
NCT05753462,Sqy Therapeutics,"Phase 1/2a, Monocentric, Open Label Study to Evaluate the Safety, PK and PD of SQY51 in Paediatric and Adult Patients With a Genetically Confirmed Diagnosis of Duchenne Muscular Dystrophy",2023-02-06,2025-02,RECRUITING,ASO,HÃ´pital Raymond PoincarÃ©,48.84226,2.18232
NCT03564561,Assistance Publique - Hôpitaux de Paris,Clinical and Molecular Aspects of Adult Onset Pompe Disease: a Natural History Study,2018-03-27,2033-03,RECRUITING,ASO,HÃ´pital Raymond PoincarÃ©,48.84226,2.18232
NCT03907072,Wave Life Sciences Ltd.,"A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)",2019-04-05,2020-01-09,TERMINATED,ASO,HÃ´pital des Enfants,43.60426,1.44367
NCT01346150,National Institute of Allergy and Infectious Diseases (NIAID),"A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)",2011-04-29,2023-08,UNKNOWN,gene_therapy,BC Children's Hospital,49.24966,-123.11934
NCT01186913,National Institute of Allergy and Infectious Diseases (NIAID),"A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)",2010-08-20,2028-09,ENROLLING_BY_INVITATION,gene_therapy,BC Children's Hospital,49.24966,-123.11934
NCT06063850,UniQure Biopharma B.V.,"A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)",2023-09-01,2027-06-30,RECRUITING,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT06275620,Beacon Therapeutics,"A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa",2024-02-16,2029-12,ENROLLING_BY_INVITATION,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05386680,Novartis,"Phase IIIb, Open-label, Single-arm, Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally (1.2 x 10^14 Vector Genomes) to Participants 2 to < 18 Years of Age With Spinal Muscular Atrophy (SMA) Who Have Discontinued Treatment With Nusinersen (Spinraza®) or Risdiplam (Evrysdi®)",2022-05-18,2024-11-29,COMPLETED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05898620,Neurogene Inc.,"A Phase 1/2, Open-Label Clinical Study to Evaluate Safety, Tolerability, and Efficacy of NGN-401 in Pediatric Subjects with Rett Syndrome",2023-06-01,2029-10,RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT04680065,"Brain Neurotherapy Bio, Inc.","Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy",2020-12-15,2028-12,RECRUITING,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT01301573,"Neurologix, Inc.",Long Term Follow-Up Study for rAAV-GAD Treated Subjects,2011-02-18,unknown,TERMINATED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT05145062,Sangamo Therapeutics,An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant,2021-11-22,2038-07-14,ENROLLING_BY_INVITATION,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05699460,AskBio Inc,A Pre-Gene Therapy Study of Early Parkinson's or Multiple System Atrophy Progression by Longitudinal Clinical and Biomarker Assessments,2022-10-13,2025-10,ACTIVE_NOT_RECRUITING,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT03432520,"Spark Therapeutics, Inc.",A Multi-Center Evaluation of the Long-Term Safety and Efficacy of Spark-sponsored Gene Therapies in Males With Hemophilia A,2018-01-24,2032-12,ACTIVE_NOT_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT01410825,Boston Children's Hospital,Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome,2011-08-04,2024-08,ACTIVE_NOT_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05248230,4D Molecular Therapeutics,"An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults with Cystic Fibrosis",2022-02-10,2030-01,RECRUITING,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT05248230,4D Molecular Therapeutics,"An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults with Cystic Fibrosis",2022-02-10,2030-01,RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT01952730,Massachusetts General Hospital,"A Pilot Safety Study of Vaccination With Autologous, Lethally Irradiated Colorectal Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor",2013-04-26,2020-02,TERMINATED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT04166526,Boston Children's Hospital,A Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease,2019-10-15,2026-08-01,RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT00438867,Cardium Therapeutics,"A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Female Patients With Stable Angina Pectoris Who Are Not Candidates for Revascularization",2007-02-21,unknown,UNKNOWN,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT01129544,Boston Children's Hospital,Multi-site Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer,2010-05-21,2023-03,COMPLETED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT03381729,Novartis,"Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy",2017-12-13,2021-11-18,TERMINATED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05660369,Massachusetts General Hospital,INCIPIENT: INtraventricular CARv3-TEAM-E T Cells for PatIENTs With GBM,2022-12-13,2026-06-01,RECRUITING,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT02991144,Ultragenyx Pharmaceutical Inc,"A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency",2016-12-09,2021-12-16,COMPLETED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT00073463,Targeted Genetics Corporation,"A Multicenter, Double-Blind, Placebo Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis",2003-11-21,2005-10,TERMINATED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT00073463,Targeted Genetics Corporation,"A Multicenter, Double-Blind, Placebo Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis",2003-11-21,2005-10,TERMINATED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT06297486,"Spark Therapeutics, Inc.","A Phase 3, Single-arm, Open-label, Multicenter Study of the Safety and Efficacy of Dirloctocogene Samoparvovec (SPK 8011, Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene) in Adults With Severe or Moderately Severe Hemophilia A",2024-02-29,2035-09-04,WITHDRAWN,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT06092034,Rocket Pharmaceuticals Inc.,Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With Danon Disease,2023-10-11,2029-09,ACTIVE_NOT_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT02234934,"University of California, Los Angeles","A Two-Part, Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease",2014-09-04,2024-12-01,COMPLETED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT01071941,Massachusetts General Hospital,rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors,2010-01-13,2024-06,TERMINATED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT02599922,Beacon Therapeutics,"A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene",2015-11-05,2026-07,ACTIVE_NOT_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05606614,"Taysha Gene Therapies, Inc.","REVEAL Adult Study: an Open-label, Randomized, Doseescalation- and Dose-expansion Study of the Safety and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, in the Treatment of Adult Females with Rett Syndrome",2022-10-28,2032-01-05,RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT03636438,Ultragenyx Pharmaceutical Inc,A Long-Term Follow-up Study to Evaluate Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency,2018-08-15,2029-12,ACTIVE_NOT_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05881408,"Sarepta Therapeutics, Inc.","A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP- 9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (ENVISION)",2023-05-19,2028-06-30,RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT00117650,Sanofi,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in Patients With Intermittent Claudication",2005-06-30,2010-03,COMPLETED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT01346150,National Institute of Allergy and Infectious Diseases (NIAID),"A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)",2011-04-29,2023-08,UNKNOWN,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT01186913,National Institute of Allergy and Infectious Diseases (NIAID),"A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)",2010-08-20,2028-09,ENROLLING_BY_INVITATION,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT06333249,Beacon Therapeutics,"A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Confirmed by a Pathogenic Variant in the RPGR Gene",2024-02-16,2027-02,ACTIVE_NOT_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05821959,"Akouos, Inc.",A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss Due to Otoferlin Gene Mutations,2023-02-08,2028-10,RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05096221,"Sarepta Therapeutics, Inc.","A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)",2021-10-14,2024-10-25,COMPLETED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT06285643,AskBio Inc,"A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease",2024-02-14,2027-11-30,RECRUITING,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT06285643,AskBio Inc,"A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease",2024-02-14,2027-11-30,RECRUITING,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT06483802,Astellas Pharma Inc,"A Multicenter, Open-Label, Dose Escalation, Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2016 for Friedreich Ataxia Cardiomyopathy",2024-06-26,2031-01-31,SUSPENDED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT06647979,Boston Children's Hospital,Pilot and Feasibility Trial: Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe Β-Hemoglobinopathies,2024-10-11,2030-12,NOT_YET_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT00643890,"Neurologix, Inc.",Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease,2008-03-24,unknown,TERMINATED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT03311503,Boston Children's Hospital,Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 with Low Dose Targeted Busulfan Conditioning,2017-10-12,2028-10-01,RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT00003942,National Cancer Institute (NCI),A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support,1999-11-01,unknown,UNKNOWN,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT03505099,Novartis,"A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2",2018-04-13,2021-06-15,COMPLETED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT03952156,"Homology Medicines, Inc","A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency",2019-05-09,2023-08-01,TERMINATED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT06152237,"Taysha Gene Therapies, Inc.","A Multicenter, Open Label, Randomized, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females with Rett Syndrome",2023-11-21,2031-11-02,RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT02618915,Ultragenyx Pharmaceutical Inc,Phase I/II Open-Label Safety and Dose Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B,2015-11-23,2017-10-18,TERMINATED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT00809588,Dana-Farber Cancer Institute,"A Phase IB Study of Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor",2008-12-16,2020-02-25,COMPLETED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT00031083,Biogen,"A Multi-center, Open Label, Two Part, Dose Escalation Study to Determine the Tolerability of Interferon-Beta Gene Transfer (BG00001) in the Treatment of Recurrent or Progressive Grade III and Grade IV Gliomas",2002-02-20,2003-10-10,COMPLETED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT03282656,Boston Children's Hospital,Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease,2017-08-22,2024-12-13,ACTIVE_NOT_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT04884815,Ultragenyx Pharmaceutical Inc,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease",2021-05-07,2031-11,ACTIVE_NOT_RECRUITING,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT04903288,PTC Therapeutics,An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects,2021-05-21,2028-04-30,ACTIVE_NOT_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT04126005,Aspa Therapeutics,A Combination Retrospective Medical History and Prospective Observational Study of Patients With Canavan Disease for Assessment of Natural History of Canavan Disease,2019-10-10,2026-04-30,RECRUITING,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT02786511,Celgene,Longterm Follow-up of Subjects Treated With bb2121,2016-05-26,2019-10-11,COMPLETED,gene_therapy,Massachusetts General Hospital,42.35843,-71.05977
NCT00258687,Dana-Farber Cancer Institute,"A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients",2005-11-23,2020-12,COMPLETED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT03003533,"Spark Therapeutics, Inc.","Gene-transfer, Open-label, Dose-escalation Study of SPK-8011 [Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene] in Individuals With Hemophilia A",2016-12-16,2023-12-05,COMPLETED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT02064933,National Institute of Allergy and Infectious Diseases (NIAID),"Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)",2014-02-13,2019-05-01,COMPLETED,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT05353647,Boston Children's Hospital,"A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell (GRASP, BMT CTN 2001)",2022-04-21,2026-05,ACTIVE_NOT_RECRUITING,gene_therapy,Boston Children's Hospital,42.35843,-71.05977
NCT04684940,BioMarin Pharmaceutical,"A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Active or Prior Inhibitors",2020-11-30,2029-04,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT05878860,Atsena Therapeutics Inc.,"A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Tolerability of ATSN-201 Gene Therapy in Male Subjects With RS1-Associated X-linked Retinoschisis",2023-05-12,2029-10,RECRUITING,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT03569891,CSL Behring,"Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B",2018-06-14,2025-03,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT04794101,"Janssen Research & Development, LLC",Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene,2020-12-15,2029-12-19,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT01687608,Takeda,"A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B",2012-08-27,2030-01-17,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT01346150,National Institute of Allergy and Infectious Diseases (NIAID),"A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)",2011-04-29,2023-08,UNKNOWN,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT01186913,National Institute of Allergy and Infectious Diseases (NIAID),"A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)",2010-08-20,2028-09,ENROLLING_BY_INVITATION,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT03597399,"Spark Therapeutics, Inc.","A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in US",2018-07-12,2025-06,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT05164471,Spur Therapeutics,A Dose Confirmation Study of FLT180a (Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene) in Adult Subjects With Hemophilia B,2021-11-22,2023-05-31,TERMINATED,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT01852071,"University of California, Los Angeles",Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID),2013-05-07,2018-08-27,COMPLETED,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT04398628,American Thrombosis and Hemostasis Network,"ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders",2020-05-11,2035-12,RECRUITING,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT04671433,"Janssen Research & Development, LLC","Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene",2020-11-05,2024-09-30,COMPLETED,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT05353647,Boston Children's Hospital,"A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell (GRASP, BMT CTN 2001)",2022-04-21,2026-05,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT04272554,Spur Therapeutics,Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE),2020-02-10,2022-10-10,COMPLETED,gene_therapy,Children's Hospital Los Angeles,34.05223,-118.24368
NCT04737460,University of Texas Southwestern Medical Center,Phase 1 Intrathecal Lumbar Administration of AAV9/CLN7 for Treatment of CLN7 Disease,2021-01-15,2029-02-01,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Health Dallas,32.78306,-96.80667
NCT03505099,Novartis,"A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2",2018-04-13,2021-06-15,COMPLETED,gene_therapy,Children's Health Dallas,32.78306,-96.80667
NCT05518188,Elpida Therapeutics SPC,A Phase 1/2 Open-label Intrathecal Administration of MELPIDA to Determine Its Safety and Efficacy for Patients with Spastic Paraplegia Type 50 (SPG50) Caused by Mutation in the AP4M1 Gene.,2022-08-24,2030-10-01,RECRUITING,gene_therapy,Children's Health Dallas,32.78306,-96.80667
NCT05898620,Neurogene Inc.,"A Phase 1/2, Open-Label Clinical Study to Evaluate Safety, Tolerability, and Efficacy of NGN-401 in Pediatric Subjects with Rett Syndrome",2023-06-01,2029-10,RECRUITING,gene_therapy,Children's Health Colorado,39.72943,-104.83192
NCT02991144,Ultragenyx Pharmaceutical Inc,"A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency",2016-12-09,2021-12-16,COMPLETED,gene_therapy,Children's Health Colorado,39.72943,-104.83192
NCT05861986,Hoffmann-La Roche,A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy,2023-05-08,2028-03-31,RECRUITING,gene_therapy,Children's Health Colorado,39.72943,-104.83192
NCT05139316,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients with Glycogen Storage Disease Type Ia",2021-07-14,2026-02,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Health Colorado,39.72943,-104.83192
NCT03636438,Ultragenyx Pharmaceutical Inc,A Long-Term Follow-up Study to Evaluate Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency,2018-08-15,2029-12,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Health Colorado,39.72943,-104.83192
NCT05861999,Hoffmann-La Roche,A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy,2023-05-08,2028-03-31,RECRUITING,gene_therapy,Children's Health Colorado,39.72943,-104.83192
NCT05096221,"Sarepta Therapeutics, Inc.","A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)",2021-10-14,2024-10-25,COMPLETED,gene_therapy,Children's Health Colorado,39.72943,-104.83192
NCT03505099,Novartis,"A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2",2018-04-13,2021-06-15,COMPLETED,gene_therapy,Children's Health Colorado,39.72943,-104.83192
NCT03505099,Novartis,"A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2",2018-04-13,2021-06-15,COMPLETED,gene_therapy,Children's Hospital of Eastern Ontario,45.41117,-75.69812
NCT04281485,Pfizer,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY",2020-02-11,2039-04-15,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Eastern Ontario,45.41117,-75.69812
NCT03307980,Pfizer,"A FACTOR IX (FIX) GENE TRANSFER, MULTI CENTER EVALUATION OF THE LONG TERM SAFETY AND EFFICACY STUDY OF PF 06838435 AND A DOSE ESCALATION SUBSTUDY IN INDIVIDUALS WITH HEMOPHILIA B",2017-09-29,2029-06-06,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05878860,Atsena Therapeutics Inc.,"A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Tolerability of ATSN-201 Gene Therapy in Male Subjects With RS1-Associated X-linked Retinoschisis",2023-05-12,2029-10,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03432520,"Spark Therapeutics, Inc.",A Multi-Center Evaluation of the Long-Term Safety and Efficacy of Spark-sponsored Gene Therapies in Males With Hemophilia A,2018-01-24,2032-12,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT00076557,Avigen,A Phase I Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using Adeno-Associated Viral Vector to Deliver the Gene for Human Factor IX Into the Liver,2004-01-26,unknown,TERMINATED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT01620801,"Spark Therapeutics, Inc.","A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX",2012-06-12,2016-03,TERMINATED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03381729,Novartis,"Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy",2017-12-13,2021-11-18,TERMINATED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05885412,Rocket Pharmaceuticals Inc.,A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human Plakophilin-2a (PKP2a) Coding Sequence (RP-A601; AAVrh.74-PKP2a) in Subjects With Arrhythmogenic Cardiomyopathy Arising From Pathogenic PKP2 Variants (PKP2-ACM),2023-05-22,2026-09,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT02484092,Pfizer,"Gene Therapy, Open-label, Dose-escalation Study of PF-06838435 (SPK-9001) [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B",2015-06-18,2019-04-08,COMPLETED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05861986,Hoffmann-La Roche,A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene Therapy,2023-05-08,2028-03-31,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05429372,Pfizer,"A PHASE 2, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND DYSTROPHIN EXPRESSION AFTER FORDADISTROGENE MOVAPARVOVEC (PF-06939926) ADMINISTRATION IN MALE PARTICIPANTS WITH EARLY STAGE DUCHENNE MUSCULAR DYSTROPHY",2021-10-08,2029-01-03,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05429372,Pfizer,"A PHASE 2, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND DYSTROPHIN EXPRESSION AFTER FORDADISTROGENE MOVAPARVOVEC (PF-06939926) ADMINISTRATION IN MALE PARTICIPANTS WITH EARLY STAGE DUCHENNE MUSCULAR DYSTROPHY",2021-10-08,2029-01-03,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT04783181,Adrenas Therapeutics Inc,"A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene",2021-03-01,2029-02,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT06092034,Rocket Pharmaceuticals Inc.,Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With Danon Disease,2023-10-11,2029-09,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT04591834,REGENXBIO Inc.,"A Prospective, Observational Study of Pediatric Patients With Neuronopathic Forms of MPS II (Hunter Syndrome)",2020-09-23,2025-07,WITHDRAWN,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05139316,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients with Glycogen Storage Disease Type Ia",2021-07-14,2026-02,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT06364774,Children's Hospital of Philadelphia,Phase 1/2 Study Evaluating the Safety and Efficacy of Gene Therapy Employing Lentiviral Vector ALS20-transduced Hematopoietic Progenitor Cells in Subjects With Transfusion-dependent-thalassemia,2024-03-26,2027-12-31,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05568719,Pfizer,"A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY",2022-10-03,2039-09-03,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05881408,"Sarepta Therapeutics, Inc.","A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP- 9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (ENVISION)",2023-05-19,2028-06-30,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT00515710,"Spark Therapeutics, Inc.",A Long-Term Follow-Up Study in Subjects With Sever Hemophilia B Who Received Adeno-Associated Viral Vectors Expressing Human Factor IX,2007-08-10,2017-12,COMPLETED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT01346150,National Institute of Allergy and Infectious Diseases (NIAID),"A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)",2011-04-29,2023-08,UNKNOWN,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03566043,REGENXBIO Inc.,"A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)",2018-05-01,2025-08,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT01186913,National Institute of Allergy and Infectious Diseases (NIAID),"A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)",2010-08-20,2028-09,ENROLLING_BY_INVITATION,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT06246513,"Sarepta Therapeutics, Inc.","A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects With Limb Girdle Muscular Dystrophy 2E/R4",2024-01-30,2029-11-30,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT06270719,"Sarepta Therapeutics, Inc.",A Long-term Multicenter Prospective Observational Study Evaluating the Comparative Effectiveness and Safety of Sarepta Gene Transfer Therapy vs. Standard of Care in Participants With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice,2024-01-24,2038-12-31,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05821959,"Akouos, Inc.",A Trial of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss Due to Otoferlin Gene Mutations,2023-02-08,2028-10,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT05096221,"Sarepta Therapeutics, Inc.","A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)",2021-10-14,2024-10-25,COMPLETED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT06149403,Orchard Therapeutics,"A Multi-center, Randomized, Active Controlled Clinical Trial to Evaluate the Efficacy and Safety of OTL-203 in Subjects with Mucopolysaccharidosis Type I, Hurler Syndrome (MPS-IH) Compared to Standard of Care with Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)",2023-11-17,2031-03,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03597399,"Spark Therapeutics, Inc.","A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in US",2018-07-12,2025-06,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT04281485,Pfizer,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY",2020-02-11,2039-04-15,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03952156,"Homology Medicines, Inc","A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency",2019-05-09,2023-08-01,TERMINATED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT04628585,bluebird bio,Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector,2020-11-05,2038-01,ENROLLING_BY_INVITATION,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT06152237,"Taysha Gene Therapies, Inc.","A Multicenter, Open Label, Randomized, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females with Rett Syndrome",2023-11-21,2031-11-02,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03882437,Rocket Pharmaceuticals Inc.,A Clinical Study Evaluating a Recombinant Adeno-Associated Virus Serotype 9 (rAAV9) Capsid Containing the Human Lysosome-Associated Membrane Protein 2 Isoform B (LAMP2B) Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With DD,2019-03-12,2025-03-24,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT06075537,Denali Therapeutics Inc.,"An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007",2023-09-18,2027-06,ENROLLING_BY_INVITATION,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT00999609,"Spark Therapeutics, Inc.",A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301],2009-10-21,2029-07,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT02341807,"Spark Therapeutics, Inc.",A Phase 1/2 Safety Study in Subjects With CHM (Choroideremia) Gene Mutations Using an Adeno-Associated Virus Serotype 2 Vector to Deliver the Normal Human CHM Gene [AAV2-hCHM] to the Retina,2015-01-12,2022-10-12,COMPLETED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03734588,"Spark Therapeutics, Inc.",Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors,2018-11-06,2023-01-19,COMPLETED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03207009,bluebird bio,A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector in Subjects ≤50 Years of Age,2017-06-29,2022-11-15,COMPLETED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT06636383,Ultragenyx Pharmaceutical Inc,GSDIa Disease Monitoring Program,2024-09-20,2036-12,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03580083,REGENXBIO Inc.,"A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Intracisternal RGX-111 in Subjects With Mucopolysaccharidosis Type I",2018-06-18,2024-10,ACTIVE_NOT_RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT04398628,American Thrombosis and Hemostasis Network,"ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders",2020-05-11,2035-12,RECRUITING,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT03003533,"Spark Therapeutics, Inc.","Gene-transfer, Open-label, Dose-escalation Study of SPK-8011 [Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene] in Individuals With Hemophilia A",2016-12-16,2023-12-05,COMPLETED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT02064933,National Institute of Allergy and Infectious Diseases (NIAID),"Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)",2014-02-13,2019-05-01,COMPLETED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT00516477,"Spark Therapeutics, Inc.",A Phase 1 Safety Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 Into the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-101],2007-08-13,2018-03-20,COMPLETED,gene_therapy,Children's Hospital of Philadelphia,39.95233,-75.16379
NCT04398628,American Thrombosis and Hemostasis Network,"ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders",2020-05-11,2035-12,RECRUITING,gene_therapy,Children's Mercy Kansas City,39.09973,-94.57857
NCT05039866,Sangamo Therapeutics,"Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy",2021-08-20,2029-06,ENROLLING_BY_INVITATION,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT00272857,Boston Children's Hospital,"Gene Transfer From Patients With Fanconi Anemia, Genotype A: A Pilot Study",2006-01-04,2007-10,COMPLETED,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT01129544,Boston Children's Hospital,Multi-site Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer,2010-05-21,2023-03,COMPLETED,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT06297486,"Spark Therapeutics, Inc.","A Phase 3, Single-arm, Open-label, Multicenter Study of the Safety and Efficacy of Dirloctocogene Samoparvovec (SPK 8011, Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene) in Adults With Severe or Moderately Severe Hemophilia A",2024-02-29,2035-09-04,WITHDRAWN,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT01054339,Beacon Therapeutics,"A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients With Alpha-1 Antitrypsin Deficiency",2010-01-21,2015-10,COMPLETED,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT03041324,Sangamo Therapeutics,"A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)",2017-01-13,2021-05-07,TERMINATED,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT04046224,Sangamo Therapeutics,"A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)",2019-08-01,2025-09,ACTIVE_NOT_RECRUITING,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT01346150,National Institute of Allergy and Infectious Diseases (NIAID),"A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)",2011-04-29,2023-08,UNKNOWN,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT01186913,National Institute of Allergy and Infectious Diseases (NIAID),"A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)",2010-08-20,2028-09,ENROLLING_BY_INVITATION,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT05761899,"Children's Hospital Medical Center, Cincinnati",A First-In-Human Clinical Trial of Lentiviral-mediated CSF2RA Gene Transfer/Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis,2023-02-28,2038-10-01,RECRUITING,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT06483802,Astellas Pharma Inc,"A Multicenter, Open-Label, Dose Escalation, Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2016 for Friedreich Ataxia Cardiomyopathy",2024-06-26,2031-01-31,SUSPENDED,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT03311503,Boston Children's Hospital,Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 with Low Dose Targeted Busulfan Conditioning,2017-10-12,2028-10-01,RECRUITING,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT02186418,"Children's Hospital Medical Center, Cincinnati",Gene Transfer For Patients With Sickle Cell Disease Using A Gamma Globin Lentivirus Vector: An Open-Label Phase 1 / 2 Pilot Study,2014-06-30,2022-10-31,TERMINATED,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT06075537,Denali Therapeutics Inc.,"An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007",2023-09-18,2027-06,ENROLLING_BY_INVITATION,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT04628871,Sangamo Therapeutics,"Long-Term Follow-up of Subjects Who Were Treated With SB-318, SB-913, or SB-FIX, for Targeted Genome Editing Into the Albumin Gene in the Liver",2020-11-09,2030-01-01,ACTIVE_NOT_RECRUITING,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT04903288,PTC Therapeutics,An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects,2021-05-21,2028-04-30,ACTIVE_NOT_RECRUITING,gene_therapy,Cincinnati Children's Hospital,39.12713,-84.51435
NCT05230459,AskBio Inc,"A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I/R9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)",2022-01-27,2028-12,RECRUITING,gene_therapy,Kennedy Krieger Institute,39.29038,-76.61219
NCT03767348,Replimune Inc.,"An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors",2018-12-05,2028-12,RECRUITING,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT06228924,Tenaya Therapeutics,"First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-401, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Plakophilin-2 (PKP2) Transgene, in Adults With PKP2 Mutation-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)",2024-01-18,2029-10-01,RECRUITING,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT05445323,Lexeo Therapeutics,A Phase 1/2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich's Ataxia,2022-06-23,2029-09,ACTIVE_NOT_RECRUITING,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT06311708,Tenaya Therapeutics,Seroprevalence Study of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC),2024-03-08,2030-07-11,RECRUITING,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT01186913,National Institute of Allergy and Infectious Diseases (NIAID),"A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)",2010-08-20,2028-09,ENROLLING_BY_INVITATION,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT05407636,AbbVie,"A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD",2022-01-28,2026-11,RECRUITING,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT04850118,Beacon Therapeutics,"A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants With X-linked Retinitis Pigmentosa",2021-04-05,2029-10,RECRUITING,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT05836259,Tenaya Therapeutics,"First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)",2023-04-18,2032-08,RECRUITING,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT00044356,Vical,A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma,2002-08-26,2004-09,COMPLETED,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT06682793,A2 Biotherapeutics Inc.,"A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",2024-11-07,2030-03-31,NOT_YET_RECRUITING,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT06517888,"Akouos, Inc.",A Phase 1/2 Trial of AAVAnc80-antiVEGF Gene Therapy in Individuals With Unilateral Vestibular Schwannoma,2024-07-19,2029-08,RECRUITING,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT00788307,Mayo Clinic,Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine,2008-11-07,2018-02-07,TERMINATED,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT00121745,Epeius Biotechnologies,Phase I Evaluation of Safety of Intravenous Infusion of a Pathotropic Vector Bearing a Cytocidal Cyclin G1 Construct (Rexin-G) as Intervention for Locally Advanced and Metastatic Pancreatic Cancer Refractory to Standard Chemotherapy,2005-07-15,2007-07,TERMINATED,gene_therapy,Mayo Clinic,44.02163,-92.4699
NCT06270719,"Sarepta Therapeutics, Inc.",A Long-term Multicenter Prospective Observational Study Evaluating the Comparative Effectiveness and Safety of Sarepta Gene Transfer Therapy vs. Standard of Care in Participants With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice,2024-01-24,2038-12-31,RECRUITING,gene_therapy,Nicklaus Children's Hospital,25.77427,-80.19366
NCT03562494,Neurocrine Biosciences,"A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations",2018-05-16,2024-10-30,COMPLETED,gene_therapy,NYU Langone Health,40.71427,-74.00597
NCT04680065,"Brain Neurotherapy Bio, Inc.","Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy",2020-12-15,2028-12,RECRUITING,gene_therapy,NYU Langone Health,40.71427,-74.00597
NCT01161576,Weill Medical College of Cornell University,Direct CNS Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human CLN2 cDNA to Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL),2010-03-22,2020-12-31,COMPLETED,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT02193191,Memorial Sloan Kettering Cancer Center,Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease,2014-07-15,2025-07,ACTIVE_NOT_RECRUITING,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT03767348,Replimune Inc.,"An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors",2018-12-05,2028-12,RECRUITING,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT03612869,LYSOGENE,"Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA",2018-07-04,2022-03,UNKNOWN,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT05603312,MeiraGTx UK II Ltd,"A Randomized, Double-Blind, Sham-Controlled Study to Evaluate the Safety and Tolerability of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's Disease",2022-10-12,2024-09-06,COMPLETED,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT06297486,"Spark Therapeutics, Inc.","A Phase 3, Single-arm, Open-label, Multicenter Study of the Safety and Efficacy of Dirloctocogene Samoparvovec (SPK 8011, Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene) in Adults With Severe or Moderately Severe Hemophilia A",2024-02-29,2035-09-04,WITHDRAWN,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT06228924,Tenaya Therapeutics,"First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-401, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Plakophilin-2 (PKP2) Transgene, in Adults With PKP2 Mutation-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)",2024-01-18,2029-10-01,RECRUITING,gene_therapy,NYU Langone Health,40.71427,-74.00597
NCT01174095,Weill Medical College of Cornell University,A Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA,2010-07-30,2012-05,COMPLETED,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT06051695,A2 Biotherapeutics Inc.,"A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",2023-09-18,2029-06,RECRUITING,gene_therapy,NYU Langone Health,40.71427,-74.00597
NCT05894343,MeiraGTx UK II Ltd,Long-term Follow-up of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's Disease,2023-05-30,2029-10,ENROLLING_BY_INVITATION,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT01414985,Weill Medical College of Cornell University,Direct CNS Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human CLN2 cDNA to Children With LINCL With Uncommon Genotypes and/or Moderate to Severe Impairment,2010-12-13,2017-02-08,COMPLETED,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT06682793,A2 Biotherapeutics Inc.,"A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",2024-11-07,2030-03-31,NOT_YET_RECRUITING,gene_therapy,NYU Langone Health,40.71427,-74.00597
NCT03734588,"Spark Therapeutics, Inc.",Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors,2018-11-06,2023-01-19,COMPLETED,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT03634007,Lexeo Therapeutics,"A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease",2018-08-03,2024-11-07,COMPLETED,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT05302271,Weill Medical College of Cornell University,Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia,2022-03-21,2029-12-31,RECRUITING,gene_therapy,Weill Cornell Medicine,40.71427,-74.00597
NCT04126005,Aspa Therapeutics,A Combination Retrospective Medical History and Prospective Observational Study of Patients With Canavan Disease for Assessment of Natural History of Canavan Disease,2019-10-10,2026-04-30,RECRUITING,gene_therapy,NYU Langone Health,40.71427,-74.00597
NCT05881408,"Sarepta Therapeutics, Inc.","A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP- 9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (ENVISION)",2023-05-19,2028-06-30,RECRUITING,gene_therapy,Rady Children's Hospital,32.71533,-117.15726
NCT04398628,American Thrombosis and Hemostasis Network,"ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders",2020-05-11,2035-12,RECRUITING,gene_therapy,Rady Children's Hospital,32.71533,-117.15726
NCT03970382,"PACT Pharma, Inc.","A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors",2019-05-06,2022-08-12,SUSPENDED,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT00051480,GenVec,"A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer",2003-01-10,unknown,COMPLETED,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT05898620,Neurogene Inc.,"A Phase 1/2, Open-Label Clinical Study to Evaluate Safety, Tolerability, and Efficacy of NGN-401 in Pediatric Subjects with Rett Syndrome",2023-06-01,2029-10,RECRUITING,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT00087789,Sangamo Therapeutics,"A Phase I, Dose-Escalating Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-Based Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects With Mild to Moderate Alzheimer's Disease",2004-07-13,2010-05,COMPLETED,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT01082094,"Juventas Therapeutics, Inc.",An Open Label Dose Escalation Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure,2010-03-04,2012-01,COMPLETED,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT00985517,Sangamo Therapeutics,A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease,2009-09-25,2017-11-16,COMPLETED,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT05606614,"Taysha Gene Therapies, Inc.","REVEAL Adult Study: an Open-label, Randomized, Doseescalation- and Dose-expansion Study of the Safety and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, in the Treatment of Adult Females with Rett Syndrome",2022-10-28,2032-01-05,RECRUITING,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT00090714,Corautus Genetics,To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter,2004-09-02,unknown,UNKNOWN,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT01687608,Takeda,"A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B",2012-08-27,2030-01-17,ACTIVE_NOT_RECRUITING,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT00252850,Sangamo Therapeutics,"A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease",2005-11-11,2007-03,COMPLETED,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT03544723,"MultiVir, Inc.","A Phase 2, Multi-Center, Open Label Study to Evaluate Adenoviral p53 (Ad-p53) in Combination With Immune Checkpoint Inhibitor Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Tumors Approved for Anti-PD-1 or Anti-PD-L1 Therapy",2018-05-09,2022-12-31,UNKNOWN,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT00117650,Sanofi,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in Patients With Intermittent Claudication",2005-06-30,2010-03,COMPLETED,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT06152237,"Taysha Gene Therapies, Inc.","A Multicenter, Open Label, Randomized, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females with Rett Syndrome",2023-11-21,2031-11-02,RECRUITING,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT04180215,Hookipa Biotech GmbH,A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers,2019-09-20,2026-06,ACTIVE_NOT_RECRUITING,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT04120493,UniQure Biopharma B.V.,"A Phase I/II, Randomized, Double-Blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered RAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease",2019-09-30,2029-06,RECRUITING,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT04398628,American Thrombosis and Hemostasis Network,"ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders",2020-05-11,2035-12,RECRUITING,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT04272554,Spur Therapeutics,Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE),2020-02-10,2022-10-10,COMPLETED,gene_therapy,Rush University Medical Center,41.85003,-87.65005
NCT05898620,Neurogene Inc.,"A Phase 1/2, Open-Label Clinical Study to Evaluate Safety, Tolerability, and Efficacy of NGN-401 in Pediatric Subjects with Rett Syndrome",2023-06-01,2029-10,RECRUITING,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT02416622,Beacon Therapeutics,"A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis",2015-04-02,2023-05-09,COMPLETED,gene_therapy,Baylor College of Medicine,29.76328,-95.36327
NCT00005057,National Cancer Institute (NCI),A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of Ganciclovir in Patients With Cutaneous Metastatic Malignant Melanoma,2000-04-06,unknown,COMPLETED,gene_therapy,Baylor College of Medicine,29.76328,-95.36327
NCT03612869,LYSOGENE,"Open-label, Single-arm, Multi-center Study of Intracerebral Administration of Adeno-associated Viral (AAV) Serotype rh.10 Carrying Human N-sulfoglucosamine Sulfohydrolase (SGSH) cDNA for Treatment of Mucopolysaccharidosis Type IIIA",2018-07-04,2022-03,UNKNOWN,gene_therapy,"Baylor College of Medicine, Texas Children's Hospital",29.76328,-95.36327
NCT00902044,Baylor College of Medicine,Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects With Advanced Sarcoma (HEROS),2009-05-13,2032-07,ACTIVE_NOT_RECRUITING,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT00985517,Sangamo Therapeutics,A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease,2009-09-25,2017-11-16,COMPLETED,gene_therapy,Baylor College of Medicine,29.76328,-95.36327
NCT00109655,Cell Genesys,A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure,2005-05-02,2010-09,UNKNOWN,gene_therapy,Baylor College of Medicine,29.76328,-95.36327
NCT00062855,Baylor College of Medicine,Phase I Study of Chemokine and Cytokine Gene Modified Autologous Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma Using an Adenoviral Vector (CYCHE),2003-06-17,2006-03,COMPLETED,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT00117650,Sanofi,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in Patients With Intermittent Claudication",2005-06-30,2010-03,COMPLETED,gene_therapy,Baylor College of Medicine,29.76328,-95.36327
NCT01346150,National Institute of Allergy and Infectious Diseases (NIAID),"A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)",2011-04-29,2023-08,UNKNOWN,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT01186913,National Institute of Allergy and Infectious Diseases (NIAID),"A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)",2010-08-20,2028-09,ENROLLING_BY_INVITATION,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT01822652,Baylor College of Medicine,Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch Administered To Patients With Relapsed Or Refractory Neuroblastoma (GRAIN),2013-03-28,2030-10,ACTIVE_NOT_RECRUITING,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT04628585,bluebird bio,Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector,2020-11-05,2038-01,ENROLLING_BY_INVITATION,gene_therapy,Baylor College of Medicine,29.76328,-95.36327
NCT03635632,Baylor College of Medicine,Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers(GAIL-N),2018-08-13,2038-05-16,ACTIVE_NOT_RECRUITING,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT02439788,Baylor College of Medicine,3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS TO TREAT CHILDREN WITH NEUROBLASTOMA (GINAKIT),2015-05-07,2030-10,WITHDRAWN,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT04293185,bluebird bio,A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell Disease,2020-02-12,2027-11,ACTIVE_NOT_RECRUITING,gene_therapy,"Baylor College of Medicine, Texas Children's Hospital",29.76328,-95.36327
NCT00004307,National Center for Research Resources (NCRR),Therapeutic and Metabolic Studies of Urea Cycle Disorders: Part A: Nitrogen Flux and Ureagenesis; Part B (Closed): Phase I Adenovirus Vector-Mediated Gene Therapy for Ornithine Transcarbamylase Deficiency,1999-10-18,unknown,UNKNOWN,gene_therapy,Baylor College of Medicine,29.76328,-95.36327
NCT03491683,Inovio Pharmaceuticals,"An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)",2018-04-02,2025-12-31,ACTIVE_NOT_RECRUITING,gene_therapy,Baylor College of Medicine,29.76328,-95.36327
NCT04903288,PTC Therapeutics,An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects,2021-05-21,2028-04-30,ACTIVE_NOT_RECRUITING,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT04099797,Baylor College of Medicine,Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With GD2-expressing Brain Tumors (GAIL-B),2019-09-20,2039-02,RECRUITING,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT03774654,Baylor College of Medicine,Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies,2018-12-11,2035-03-01,RECRUITING,gene_therapy,Texas Children's Hospital,29.76328,-95.36327
NCT05419492,Encoded Therapeutics,"ENDEAVOR: a Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children with SCN1A-Positive Dravet Syndrome",2022-06-10,2031-04,RECRUITING,gene_therapy,UCSF Benioff Children's Hospital,37.77493,-122.41942
NCT03569891,CSL Behring,"Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B",2018-06-14,2025-03,ACTIVE_NOT_RECRUITING,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT05699460,AskBio Inc,A Pre-Gene Therapy Study of Early Parkinson's or Multiple System Atrophy Progression by Longitudinal Clinical and Biomarker Assessments,2022-10-13,2025-10,ACTIVE_NOT_RECRUITING,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT05153967,Vanderbilt University Medical Center,U01 Cooperative Assessment of Late Effects for Sickle Cell Disease Curative Therapies,2021-10-25,2026-02,RECRUITING,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT03061201,Pfizer,"A PHASE 1/2, OPEN-LABEL, ADAPTIVE, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SB-525 (PF-07055480) (RECOMBINANT AAV2/6 HUMAN FACTOR 8 GENE THERAPY) IN ADULT SUBJECTS WITH SEVERE HEMOPHILIA A",2017-02-15,2024-07-16,COMPLETED,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT01438112,"CG Oncology, Inc.","An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG",2011-09-19,2016-06,TERMINATED,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT05407636,AbbVie,"A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD",2022-01-28,2026-11,RECRUITING,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT06270719,"Sarepta Therapeutics, Inc.",A Long-term Multicenter Prospective Observational Study Evaluating the Comparative Effectiveness and Safety of Sarepta Gene Transfer Therapy vs. Standard of Care in Participants With Duchenne Muscular Dystrophy Under Conditions of Routine Clinical Practice,2024-01-24,2038-12-31,RECRUITING,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT05096221,"Sarepta Therapeutics, Inc.","A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)",2021-10-14,2024-10-25,COMPLETED,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT06285643,AskBio Inc,"A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease",2024-02-14,2027-11-30,RECRUITING,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT04120493,UniQure Biopharma B.V.,"A Phase I/II, Randomized, Double-Blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered RAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease",2019-09-30,2029-06,RECRUITING,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT04884815,Ultragenyx Pharmaceutical Inc,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease",2021-05-07,2031-11,ACTIVE_NOT_RECRUITING,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT04398628,American Thrombosis and Hemostasis Network,"ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders",2020-05-11,2035-12,RECRUITING,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT00068133,Valentis,"A Phase II Multicenter, Double-Blind, Placebo-Controlled, Trial of VLTS-589 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease",2003-09-08,2005-06,COMPLETED,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT04272554,Spur Therapeutics,Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE),2020-02-10,2022-10-10,COMPLETED,gene_therapy,Vanderbilt University Medical Center,36.16589,-86.78444
NCT03569891,CSL Behring,"Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B",2018-06-14,2025-03,ACTIVE_NOT_RECRUITING,gene_therapy,Erasmus MC,51.9225,4.47917
NCT06075537,Denali Therapeutics Inc.,"An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007",2023-09-18,2027-06,ENROLLING_BY_INVITATION,gene_therapy,Erasmus Medical Center Sophia Children's Hospital,51.9225,4.47917
NCT04272554,Spur Therapeutics,Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE),2020-02-10,2022-10-10,COMPLETED,gene_therapy,Erasmus MC,51.9225,4.47917
NCT06092034,Rocket Pharmaceuticals Inc.,Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With Danon Disease,2023-10-11,2029-09,ACTIVE_NOT_RECRUITING,gene_therapy,Angelman Center Munich,48.13743,11.57549
NCT03852498,bluebird bio,A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD),2019-02-13,2023-07-24,COMPLETED,gene_therapy,Universitaetsklinikum Leipzig,51.33962,12.37129
NCT04684940,BioMarin Pharmaceutical,"A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Active or Prior Inhibitors",2020-11-30,2029-04,ACTIVE_NOT_RECRUITING,gene_therapy,Sheba Medical Center,32.08227,34.81065
NCT03370913,BioMarin Pharmaceutical,"A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions",2017-11-27,2024-11,ACTIVE_NOT_RECRUITING,gene_therapy,Sheba Medical Center,32.08227,34.81065
NCT04127578,Prevail Therapeutics,A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL),2019-10-14,2029-06,RECRUITING,gene_therapy,Sheba Medical Center,32.08227,34.81065
NCT04903288,PTC Therapeutics,An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects,2021-05-21,2028-04-30,ACTIVE_NOT_RECRUITING,gene_therapy,Sheba Medical Center,32.08227,34.81065
NCT04797260,Leiden University Medical Center,Phase I/II Clinical Trial of Autologous Hematopoietic Stem Cell Gene Therapy in RAG1-Deficient Severe Combined Immunodeficiency,2021-03-11,2029-12-31,RECRUITING,gene_therapy,Royal Children's Hospital,-37.814,144.96332
NCT05629559,4D Molecular Therapeutics,"An Open-Label, Phase 1/2a Trial of Gene Therapy 4D-310 in Adults With Fabry Disease and Cardiac Involvement",2022-11-04,2030-01,ACTIVE_NOT_RECRUITING,gene_therapy,Royal Children's Hospital,-37.814,144.96332
NCT06112275,Encoded Therapeutics,"WAYFINDER: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome",2023-10-25,2029-12,RECRUITING,gene_therapy,Royal Children's Hospital,-37.814,144.96332
NCT04999059,AVROBIO,"A Long-Term Follow-Up Study of Subjects With Fabry Disease Who Previously Received Ex-Vivo, Lentiviral Vector-Mediated Gene-Modified Autologous Cell Therapy AVR-RD-01 in Study AVRO-RD-01-201",2021-08-04,2023-08-16,TERMINATED,gene_therapy,Royal Children's Hospital,-37.814,144.96332
NCT03454893,AVROBIO,"An Open-Label, Multinational Study Of The Efficacy And Safety of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease",2017-12-20,2022-03-14,TERMINATED,gene_therapy,Royal Children's Hospital,-37.814,144.96332
NCT04272554,Spur Therapeutics,Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE),2020-02-10,2022-10-10,COMPLETED,gene_therapy,Royal Children's Hospital,-37.814,144.96332
NCT03505099,Novartis,"A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2",2018-04-13,2021-06-15,COMPLETED,gene_therapy,Sydney Children's Hospital,-33.91439,151.24895
NCT02333760,Genethon,Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08).,2014-10-28,2032-10,ACTIVE_NOT_RECRUITING,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT04833348,Assistance Publique - Hôpitaux de Paris,"Quantification of Motor Function in Infants With Spinal Muscular Atrophy Treated With Innovative Therapies, IMUSMA Project",2021-03-23,2027-03,RECRUITING,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT06736080,Assistance Publique - Hôpitaux de Paris,"A Phase I/II Open Label Non Randomized Study, Monocentric, Single Arm, Evaluating Safety and Efficacy of Gene Therapy of FHL 3 Caused by Mutations in the Human UNC13D Gene by Transplantation of a Single Dose of Autologous CD34+ Cells Transduced Ex Vivo with the UNC13D LV Vector Expressing the UNC13D CDNA",2024-12-04,2029-01,NOT_YET_RECRUITING,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT01347346,Genethon,Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome,2011-05-03,2017-01-09,COMPLETED,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT03588299,Bayer,"A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A",2018-07-06,2026-11-03,ACTIVE_NOT_RECRUITING,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT03996824,Institut Pasteur,Study of Viral Transduction of Human Auditory Sensory Cells for the Development of Gene Therapy,2019-06-21,2027-02-18,RECRUITING,gene_therapy,Hopital La Pitie Salpetriere,48.85341,2.3488
NCT06659588,Assistance Publique - Hôpitaux de Paris,Study of Populations At Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients with Primary Immunodeficiency and Secondary Humoral Deficiency,2024-02-15,2027-01,NOT_YET_RECRUITING,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT02757911,Genethon,"A Phase I/II, Non Randomized, Monocentric Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-Linked Chronic Granulomatous Disease",2016-04-20,2034-06,ACTIVE_NOT_RECRUITING,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT06370351,Sensorion,"A Phase I/II, Open-ended, Adaptative, Open Label Dose Escalation and Expansion Clinical Trial to Evaluate the Efficacy and Safety of Unilateral Intracochlear Injection of SENS-501 Using an Injection System in Children with Severe to Profound Hearing Loss Due to Otoferlin Gene Mutations",2024-04-09,2031-07,RECRUITING,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT02678533,Assistance Publique - Hôpitaux de Paris,Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy,2016-02-05,2019-05-03,COMPLETED,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT01344798,Genethon,Phase I Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C,2011-03-17,2010-06,COMPLETED,gene_therapy,Hopital La Pitie Salpetriere,48.85341,2.3488
NCT04272554,Spur Therapeutics,Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE),2020-02-10,2022-10-10,COMPLETED,gene_therapy,HÃ´pital Necker-Enfants Malades APHP,48.85341,2.3488
NCT03207009,bluebird bio,A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector in Subjects ≤50 Years of Age,2017-06-29,2022-11-15,COMPLETED,gene_therapy,HÃ´pital de la Timone,43.29551,5.38958
NCT03893240,"Spark Therapeutics, Inc.","A Multi-Center, Low-Interventional Study With a Retrospective Component in Participants With Late-Onset Pompe Disease",2019-03-11,2020-10-27,COMPLETED,gene_therapy,HÃ´pital Raymond PoincarÃ©,48.84226,2.18232
NCT01496040,Nantes University Hospital,Prospective Monocentric Open Label Non Randomized Uncontrolled Phase I/II Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65,2011-11-24,2014-08,COMPLETED,gene_therapy,CHU de Nantes,47.21725,-1.55336
NCT06311708,Tenaya Therapeutics,Seroprevalence Study of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC),2024-03-08,2030-07-11,RECRUITING,gene_therapy,Nantes University Hospital,47.21725,-1.55336
NCT00422721,Nantes University Hospital,"Genetical, Multi-center, Prospective Study of Phenotyping and Genotyping of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy in the Aim of the Realisation of a Clinical Trial of Gene Therapy",2007-01-12,unknown,COMPLETED,gene_therapy,CHU de Nantes,47.21725,-1.55336
